Page 5,456«..1020..5,4555,4565,4575,458..5,4705,480..»

LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

Posted: Published on April 11th, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it is now offering 100 selected ProSpec-Tany TechnoGene (ProSpec) manufactured recombinant proteins related to stem cell research in its recently launched LifeMap BioReagents portal (http://bioreagents.lifemapsc.com) to researchers worldwide. ProSpecs innovative recombinant proteins, including growth factors, signaling molecules, differentiation factors, hormones, cytokines and chemokines will complement the current BioTime research product lines available via LifeMap BioReagents, including BioTimes PureStem human progenitor cell lines, PureStem packages, clinical and research grade human embryonic stem cell lines (hES), ESpan growth media for progenitor cell lines, and cell differentiation media. The addition of ProSpec products reflects LifeMap Sciences execution of its strategy to market a growing catalog of research products to aid scientists in a variety of fields, including stem cell research, developmental biology, mechanisms of various human diseases and drug and therapeutic discovery. LifeMap Sciences holds an exclusive, worldwide license to market GeneCards (www.genecards.org), the human gene compendium, and MalaCards (www.malacards.org), a database with nearly 17,000 human disease entries, from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. Additionally, it has recently launched version 1.1 of LifeMap Discovery, a comprehensive … Continue reading →

Posted in Stem Cell Research | Comments Off on LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

Vatican gets behind adult stem cell research

Posted: Published on April 11th, 2013

Vatican City Wading into one of the most controversial fields of modern medicine, the Vatican is pushing adult stem cell research as ethical and scientifically more promising than embryonic stem cell research. That's despite assertions from many in the scientific community that that it's important to pursue all types of stem cell research, including embryonic, to maximize chances of finding cures for diseases. Harvesting embryonic stem cells requires the destruction of fertilized embryos -- which are considered nascent human life in Catholic doctrine. Adult stem cells can be safely taken from adult human beings. The Vatican started promoting adult stem cells in 2011, when its Pontifical Council for Culture launched a collaboration with U.S. bio-pharmaceutical company NeoStem. The Council will host its second major conference on the issue at the Vatican this week (April 11-13), with the aim of publicizing recent research and shedding the Catholic Church's anti-science reputation. "People don't have to choose between life and science," said Robin Smith, CEO of New York-based NeoStem and president of its nonprofit arm, the Stem for Life Foundation. "We want to correct the misunderstanding in public opinion on adult stem cells. People need to understand how far we are with research." … Continue reading →

Posted in Stem Cell Research | Comments Off on Vatican gets behind adult stem cell research

Stem Cell Therapeutics Completes Trillium Merger and Issues Stock Options

Posted: Published on April 11th, 2013

TORONTO, ONTARIO--(Marketwired - Apr 9, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT"), a life sciences company developing stem cell-related technologies, today announced that it has completed its merger with Trillium Therapeutics Inc. ("Trillium") previously announced on February 4, 2013. The shareholders of Trillium voted overwhelmingly to support the merger. The company also announced the issuance of 2,560,197 stock options under its stock option plan to directors, officers and employees reflecting the addition of the executives and staff of the merged entity. The options have an exercise price of $0.25 and a term of ten years. The issuance of stock options is subject to acceptance by the TSX Venture exchange. About Stem Cell Therapeutics: Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based therapeutics through partnerships with research institutions and technology transfer organizations. SCT's objectives include the sourcing and acquisition of stem cell-related development opportunities, and securing capital for the advancement of its licensed or acquired products. The Corporation's intended corporate acquisitions and licensed acquisitions are positioning it principally in the field of cancer stem cell therapeutic development. SCT is a member of the Centre for Commercialization of Regenerative Medicine consortium. For more information, visit: http://www.stemcellthera.com. Forward Looking Statements … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell Therapeutics Completes Trillium Merger and Issues Stock Options

Research and Markets: Hematopoietic Stem Cell Transplantation – Pipeline Review, H1 2013

Posted: Published on April 11th, 2013

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013" report to their offering. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hematopoietic Stem Cell Transplantation pipeline … Continue reading →

Posted in Stem Cell Research | Comments Off on Research and Markets: Hematopoietic Stem Cell Transplantation – Pipeline Review, H1 2013

Obama Says FULLY Automatic Weapons at Sandy Hook – Video

Posted: Published on April 11th, 2013

Obama Says FULLY Automatic Weapons at Sandy Hook How many people really don't know the difference between Semi-Automatic and Fully Automatic weapons? Tag Cloud: NwoSatire Illuminati NWO Alien Invasion "New ... By: subliminalproof … Continue reading →

Comments Off on Obama Says FULLY Automatic Weapons at Sandy Hook – Video

Medical Association Foundation Fundraising Video – Video

Posted: Published on April 11th, 2013

Medical Association Foundation Fundraising Video By: minimattersllc … Continue reading →

Comments Off on Medical Association Foundation Fundraising Video – Video

Alzheimer gene ABCA7 significantly increases late-onset risk among African Americans

Posted: Published on April 11th, 2013

Public release date: 9-Apr-2013 [ | E-mail | Share ] Contact: Kim Menard kim.menard@uphs.upenn.edu 215-662-6183 University of Pennsylvania School of Medicine PHILADELPHIA - A variation in the gene ABCA7 causes a twofold increase in the risk of late onset Alzheimer disease among African Americans, according to a meta-analysis by a team of researchers including experts from the Perelman School of Medicine at the University of Pennsylvania. This is the largest analysis to date to determine genetic risk associated with late-onset Alzheimer disease (LOAD) specifically in African American individuals. The study appears in the April 10 issue of JAMA, a genomics theme issue. The Alzheimer Disease Genetics Consortium (ADGC) led by Gerard Schellenberg, PhD, professor of Pathology and Laboratory Medicine in the Perelman School of Medicine compared genetic data from nearly 6,000 African Americans over 60 years of age, with and without Alzheimer disease. The researchers found that the genotypes with the strongest association with the risk of LOAD among African Americans were ABCA7 (odds ratio, 1.8) and APOE (odds ratio, 2.3), genotypes also associated with increased risk among individuals of European ancestry. The association with ABCA7 was 60 percent stronger among African Americans than it had been observed among individuals … Continue reading →

Comments Off on Alzheimer gene ABCA7 significantly increases late-onset risk among African Americans

Association between genetic mutation and risk of death for patients with thyroid cancer

Posted: Published on April 11th, 2013

Public release date: 9-Apr-2013 [ | E-mail | Share ] Contact: Vanessa Wasta wasta@jhmi.edu 410-614-2916 The JAMA Network Journals Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear, according to a study in the April 10 issue of JAMA, a Genomics theme issue. "Papillary thyroid cancer is the most common endocrine malignancy and accounts for 85 percent to 90 percent of all thyroid cancers," according to background information in the article. "The overall 5-year patient survival rate for PTC is 95 percent to 97 percent. A major clinical challenge is how to reliably distinguish patients who need aggressive treatments to reduce mortality from those who do not. This represents a widely controversial issue in thyroid cancer medicine, particularly because of the low overall mortality of this cancer. The issue has become even more challenging given the high annual incidence of PTC." BRAF V600E is a prominent oncogene [ a gene, one or more forms of which … Continue reading →

Comments Off on Association between genetic mutation and risk of death for patients with thyroid cancer

Genetic mutations may predict who will develop chemotherapy side effects

Posted: Published on April 11th, 2013

Each cancer patients response to chemotherapy is unique. Some may experience nausea and immune deficiency, while others can experience a more severe adverse condition known as chemotherapy-induced peripheral neuropathy (CIPN) a form of nerve damage that can be so debilitating, it often prompts patients to stop treatment early. Doctors have had a hard time predicting which patients will ultimately develop CIPN, making it difficult to tailor treatment so that it is most effective for each individual. But now, new research has revealed seemingly benign genetic mutations that may influence who develops this painful side effect. In a study from the Mayo Clinic Cancer Center, researchers have implicated the genes EPHA5, ARHGEF10 and PRX as playing significant roles in the development of CIPN. This discovery can ultimately help doctors to have a better understanding of CIPN and whether or not their patients should move forward with certain cancer treatments. Chemotherapy-induced peripheral neuropathy is one of the most important, unmitigated side effects of chemotherapy, lead author Dr. Andreas Beutler, an oncologist at the Mayo Clinic Cancer Center, told FoxNews.com. You have some other side effects that used to be very important such as nausea and immune deficiency but special medications have been … Continue reading →

Comments Off on Genetic mutations may predict who will develop chemotherapy side effects

Harold M. Schmeck Jr., 89; science writer specialized in covering medical research for N.Y. Times

Posted: Published on April 11th, 2013

NEW YORK Harold M. Schmeck Jr. a science writer for The New York Times for more than 30 years who specialized in covering medical research, from the space age to the era of genetic medicine died April 1 in Hyannis. He was 89. He died after a heart attack, said his son, Peter. Mr. Schmeck, who worked at The Times from 1957 to 1989, filed exclusive articles on the health of some of the first American astronauts in the 1960s, as well as on the beginning of the effort to map the human genome in the 1980s. He wrote extensively about organ transplants, AIDS, and the federal agencies involved with public health. Mr. Schmeck wrote with conversational clarity on complicated subjects. Two American astronauts are expected to come back to Earth tomorrow tired and badly in need of shaves and showers but carrying with them the answer to one of the most important questions facing the whole United States program of space exploration, he wrote in a 1965 article about the Gemini 5 space mission, at the time the longest manned spaceflight. The question is: What are the effects on a man of a spaceflight long enough to have taken … Continue reading →

Comments Off on Harold M. Schmeck Jr., 89; science writer specialized in covering medical research for N.Y. Times

Page 5,456«..1020..5,4555,4565,4575,458..5,4705,480..»